AFP and renal cell carcinoma: In addition, after 1-month combination treatment, nicotinic acid exhibited no obvious antagonism of anticancer effect in any of the ten patients, as evidenced by their MRI result, and tumor biomarker assessment of AFP and CA199 (for advanced hepatocellular carcinoma patients) or CT assay (for patients with advanced renal cell carcinoma and metastatic thyroid carcinoma).